DURHAM – The Durham-headquartered IMMvention Therapeutix has raised nearly $2 million in new funding, according to a securities filing.
According to the filing, the total offering amount is $3,999,999 and thus far, $1,999,999 in equity funding has been raised from four investors.
In 2020, the firm raised a little more than $3.9 million and won a LaunchBio event locally before heading to a national competition.
The company followed that initial round of funding by raising an additional $2.9 million and filing an amended SEC form in 2021 that disclosed the total funding raised in the amount of $6,899,999 from five investors.
Its technology targets auto-inflammatory diseases for which there are huge unmet needs, including rheumatoid arthritis, osteoarthritis, gout and Alzheimer’s disease. Founded in 2017 by scientists from the School of Medicine and the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill who specialized in immunology and innate immunity, the company has also received loans from the North Carolina Biotechnology Center that have supported the company’s development.
Triangle startup developing therapies to fight inflammation lands $3.9M from investors
Durham life science startup IMMvention shines in LaunchBio Big Pitch competition
